• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA clears Nanobiotix to start cancer treatment trial

May 7, 2020 By Sean Whooley

Nanobiotix (PAR:NANO.PA) announced that the FDA designated its cancer treatment trial with the University of Texas MD Anderson Cancer Center as “safe to proceed.”

The trial, co-developed by Nanobiotix and MD Anderson, is set to evaluate the safety and feasibility of NBTXR3 activated-by-radiation therapy for patients with locally advanced (LAPC) or borderline resectable (BRPC) cases of pancreatic ductal adenocarcinoma (PDAC).

NBTXR3 is designed to destroy tumors through physical cell death when activated by radiotherapy. It has a high degree of biocompatibility, requires one administration before the first radiotherapy session and fits into current worldwide radiation therapy standards of care.

Nanobiotix touts the trial as the first to evaluate NBTXR3 activated-by-radiation therapy in pancreatic cancer, according to a news release.

The open-label, single-arm, prospective Phase I study includes a dose escalation to determine the recommended Phase II dose, followed by expansion at RP2D (the highest dose with acceptable toxicity). It will study adults over 18 years old with BRPC or LAPC that are radiographically non-metastatic at screening and have not previously received radiation therapy or surgery for pancreatic cancer.

Up to 24 subjects will be enrolled as Nanobiotix plans for an 18-month enrollment period with the first injection coming in the summer of 2020. Objectives include determining dose-limiting toxicity, the maximum tolerated dose and the RP2D.

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Oncology, Regulatory/Compliance Tagged With: nanobiotix, University of Texas MD Anderson Cancer Center

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS